Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

소아 및 청소년 그레이브스병 환자에서의 관해 예측 인자와 관해율

Remission rate and remission predictors of Graves disease in children and adolescents

  • 이선희 (서울대학교 의과대학 소아과학교실) ;
  • 이성용 (보라매병원 소아청소년과) ;
  • 정혜림 (분당서울대학교병원 소아청소년과) ;
  • 김재현 (서울대학교 의과대학 소아과학교실) ;
  • 김지현 (서울대학교 의과대학 소아과학교실) ;
  • 이영아 (서울대학교 의과대학 소아과학교실) ;
  • 양세원 (서울대학교 의과대학 소아과학교실) ;
  • 신충호 (서울대학교 의과대학 소아과학교실)
  • Lee, Sun Hee (Department of Pediatrics, College of Medicine, Seoul National University) ;
  • Lee, Seong Yong (Department of Pediatrics, Seoul National University Boramae Hospital) ;
  • Chung, Hye Rim (Department of Pediatrics, Seoul National University Bundang Hospital) ;
  • Kim, Jae Hyun (Department of Pediatrics, College of Medicine, Seoul National University) ;
  • Kim, Ji Hyun (Department of Pediatrics, College of Medicine, Seoul National University) ;
  • Lee, Young Ah (Department of Pediatrics, College of Medicine, Seoul National University) ;
  • Yang, Sei Won (Department of Pediatrics, College of Medicine, Seoul National University) ;
  • Shin, Choong Ho (Department of Pediatrics, College of Medicine, Seoul National University)
  • 투고 : 2009.04.22
  • 심사 : 2009.08.05
  • 발행 : 2009.09.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적:저자들은 그레이브스병으로 인한 갑상샘기능항진증을 가진 소아나 청소년에게 항갑상샘 약물 치료 전, 치료 중, 그리고 치료 종료 시에 관해를 예측할 수 있는 예측인자를 각각 찾아보고 그레이브스병의 관해율을 알아보고자 하였다. 방 법:그레이브스병으로 인한 갑상샘기능항진증으로 진단받고 3년 이상 외래 추적 관찰이 가능했던 64명의 환자를 관해를 획득한 군과 관해를 획득하지 못한 군으로 나누어 후향적으로 진단 당시의 갑상선 기능 검사와 TBII, 진단 당시 Tanner stage, 갑상샘 질환 가족력, 발현시의 증상, TBII가 정상화되는 시기와 TRH 자극 검사 시행 여부 등을 조사 분석하였다. 결 과:총 64명의 환아 중 관해가 온 환아는 37명(57.8%), 마지막 외래 추적 관찰 때 까지 관해가 오지 않은 환아는 27명(42.2%)이었다. 관해를 획득한 군과 관해를 획득하지 못한 군에서 성별이나, 발병 당시 나이, 안구돌출 여부나 진단 당시 갑상샘종의 크기, 갑상샘 질환의 가족력, 그리고 진단 당시 갑상샘 기능 검사나 TBII 수치도 차이가 없었다. 약물 치료 후 TBII가 정상화되기까지 걸리는 기간은 관해를 획득한 군은 평균 $15.5{\pm}12.07$개월, 관해를 획득하지 못한 군은 $41.69{\pm}35.70$개월로 관해를 획득한 군에서 관해를 획득하지 못한 군에 비해 유의하게 짧았다(P<0.05). 관해에 도달 한 후 TRH 자극 검사를 시행한 28명의 환아 중 정상 또는 과도한 반응을 보인 26명 중 24명(92.8%)은 마지막 외래 추적 관찰 시까지 관해를 유지하고 있었고 오직 2명(7.7%)에서만 재발하였다. 로지스틱 회귀 분석을 통해 약물 치료 후 TBII가 빨리 정상화 되는 경우 관해가 올 가능성이 높음을 알 수 있었다. 그리고 본 연구에서의 관해율은 3년에 6.3%, 6년에 55.8%로 나타났다. 결 론:치료 중 TBII가 빨리 정상화되는 것은 소아 및 청소년 그레이브스병 환자의 관해여부를 예측할 수 있는 인자가 될 수 있을 것으로 생각되며 약물 중단 시에는 TRH 자극 검사가 그레이브스병이 재발 없이 관해를 유지할 수 있는지 예측 하는데 도움을 줄 수 있을 것으로 생각된다.

Purpose:Medical therapy is the initial treatment for children with Graves disease to avoid complications of other treatments. However, optimal treatment for childhood Graves disease is controversial because most patients require relatively long periods of medical therapy and relapse is common after medication discontinuation. Therefore, this study aimed to search clinical or biochemical characteristics that could be used as remission predictors in Graves disease. Methods:We retrospectively studied children diagnosed with Graves disease, treated with anti-thyroid agents, and observed for at least 3 years. Patients were categorized into remission and non-remission groups, and the groups were compared to determine the variables that were predictive of achieving remission. Results:Sixty-four patients were enrolled, of which 37 (57.8%) achieved remission and 27 (42.2%) could not achieve remission until the last visit. Normalization of thyroid-stimulating hormone-binding inhibitory immunoglobulin (TBII) after treatment was faster in the remission group than in the non-remission group (remission group, $15.5{\pm}12.07$ vs. non-remission group, $41.69{\pm}35.70$ months). Thyrotropin-releasing hormone (TRH) stimulation tests were performed in 28 patients. Only 2 (8.3%) of 26 patients who showed normal or hyper-response in TRH stimulation test relapsed. Binary logistic regression analysis identified rapid achievement of TBII normalization after treatment as a significant predictor of remission. Six percent of patients achieved remission within 3 years and 55.8% achieved it within 6 years. Conclusion:Rapid achievement of TBII normalization can be a predictor of remission in childhood Graves disease. The TRH stimulation test can be a predictor of maintenance of remission.

키워드

참고문헌

  1. Fisher DA, Grueters A. Thyroid disorders in childhood and adolescence. In Sperling MA, editor. Pediatric Endocrinology. 3rd ed. Philadelphia : WB Saunders Co, 2008:227-53
  2. Wing SS, Fantus IG. Adverse immunologic effects of antithyroid drugs. CMAJ 1987;136:121-7
  3. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 1997;82:1727-33 https://doi.org/10.1210/jc.82.6.1727
  4. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 1983;98:26-9
  5. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997;82: 1719-26 https://doi.org/10.1210/jc.82.6.1719
  6. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019-24 https://doi.org/10.1210/jcem-60-5-1019
  7. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019-24 https://doi.org/10.1210/jcem-60-5-1019
  8. Kim H. Management of childhood hyperthyroidism. J Korean Soc Pediatr Endocrinol 1999;4:10-3
  9. Jaruratanasirikul S, Leethanaporn K, Sriplung H. Thyrotoxicosis in children: treatment and outcome. J Med Assoc Thai 2006;89:967-73
  10. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves disease undergoing remission after antithyroid drug treatment. Thyroid 1997;7: 369-75 https://doi.org/10.1089/thy.1997.7.369.
  11. Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 2006; 16:295-302 https://doi.org/10.1089/thy.2006.16.295
  12. Glaser NS, Styne DM. Predicting the likelihood of remission in children with Graves disease: a prospective, multicenter study. Pediatrics 2008;121:e481-8 https://doi.org/10.1542/peds.2007-1535
  13. Kim SY, Yu JS, Shin CH, Yang SW. The outcome of hyperthyroidism with methimazole therapy in childhood. J Korean Soc Pediatr Endocrinol 1996;1:60-8
  14. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241-5 https://doi.org/10.1210/jcem-64-6-1241
  15. Shim K. Predicted factors of remission in Graves disease. J Korean Soc Pediatr Endocrinol 2007;12:1-5
  16. Perez C, Scrimshaw NS, Munoz JA. Technique of endemic goitre surveys. Monogr Ser World Health Organ 1960;44: 369-83
  17. McGregor AM, Petersen MM, Capiferri R, Evered DC, Smith BR, Hall R. Effects of radioiodine on thyrotrophin binding inhibiting immunoglobulins in Graves disease. Clin Endocrinol (Oxf) 1979;11:437-44 https://doi.org/10.1111/j.1365-2265.1979.tb03095.x
  18. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905- 17 https://doi.org/10.1056/NEJMra042972
  19. Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves disease is surgery. J Clin Endocrinol Metab 2007;92:801-3 https://doi.org/10.1210/jc.2006-1238
  20. Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves disease is radioiodine. J Clin Endocrinol Metab 2007; 92:797-800 https://doi.org/10.1210/jc.2006-1239
  21. Kim H, Yoon J, Jung M, Suh B, Lee B. Graves disease in prepubertal children compared with pubertal children. J Korean Pediatr Soc 2003;46:76-82
  22. Zimmerman D, Lteif AN. Thyrotoxicosis in children. Endocrinol Metab Clin North Am 1998;27:109-26 https://doi.org/10.1016/S0889-8529(05)70302-9
  23. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997;7:755-60 https://doi.org/10.1089/thy.1997.7.755
  24. Gorton C, Sadeghi-Nejad A, Senior B. Remission in children with hyperthyroidism treated with propylthiouracil. Long-term results. Am J Dis Child 1987;141:1084-6 https://doi.org/10.1001/archpedi.1987.04460100062026
  25. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab 2000;85:3678-82 https://doi.org/10.1210/jc.85.10.3678
  26. Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, et al. Response to methimazole in Graves disease. The European Multicenter Study Group. Clin Endocrinol (Oxf) 1995;43: 257-63 https://doi.org/10.1111/j.1365-2265.1995.tb02030.x
  27. Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt- Rasmussen U. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves disease. Eur J Endocrinol 2002;146:173-7 https://doi.org/10.1530/eje.0.1460173
  28. Schott M, Morgenthaler NG, Fritzen R, Feldkamp J, Willenberg HS, Scherbaum WA, et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves disease. Horm Metab Res 2004;36:92-6 https://doi.org/10.1055/s-2004-814217
  29. Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves disease. Thyroid 2005;15:1047-54 https://doi.org/10.1089/thy.2005.15.1047
  30. Young ET, Steel NR, Taylor JJ, Stephenson AM, Stratton A, Holcombe M, et al. Prediction of remission after antithyroid drug treatment in Graves disease. Q J Med 1988;66:175-89
  31. Maugendre D, Massart C. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) 2001;54:89-96 https://doi.org/10.1046/j.1365-2265.2001.01197.x
  32. Teng CS, Yeung RT. Changes in thyroid-stimulating antibody activity in Graves disease treated with antithyroid drug and its relationship to relapse: a prospective study. J Clin Endocrinol Metab 1980;50:144-7 https://doi.org/10.1210/jcem-50-1-144
  33. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves disease. Acta Endocrinol (Copenh) 1989;120:689- 701
  34. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves disease with antithyroid drugs. Thyroid 1998;8:119-24 https://doi.org/10.1089/thy.1998.8.119
  35. Wilson R, McKillop JH, Henderson N, Pearson DW, Thomson JA. The ability of the serum thyrotrophin receptor antibody (TRAb) index and HLA status to predict long-term remission of thyrotoxicosis following medical therapy for Graves disease. Clin Endocrinol (Oxf) 1986;25:151-6 https://doi.org/10.1111/j.1365-2265.1986.tb01676.x
  36. Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and Graves disease--prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999;50:127-32 https://doi.org/10.1046/j.1365-2265.1999.00629.x
  37. Tamai H, Nakagawa T, Fukino O, Ohsako N, Shinzato R, Suematsu H, et al. Thionamide therapy in Graves disease: relation of relapse rate to duration of therapy. Ann Intern Med 1980;92:488-90 https://doi.org/10.7326/0003-4819-92-4-488
  38. Martino E, Pinchera A, Capiferri R, Macchia E, Sardano G, Bartalena L, et al. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism. J Clin Endocrinol Metab 1976;43:543-9 https://doi.org/10.1210/jcem-43-3-543
  39. Dahlberg PA, Karlsson FA, Jansson R, Wide L. Thyrotropin- releasing hormone testing during antithyroid drug treatment of Graves disease as an indicator of remission. J Clin Endocrinol Metab 1985;61:1100-4 https://doi.org/10.1210/jcem-61-6-1100

피인용 문헌

  1. The Clinical Course and Prognostic Factors to Medical Treatment of Graves' Disease in Children and Adolescents vol.17, pp.1, 2009, https://doi.org/10.6065/apem.2012.17.1.33
  2. The Influence of Juvenile Graves' Ophthalmopathy on Graves' Disease Course vol.2017, pp.None, 2009, https://doi.org/10.1155/2017/4853905
  3. Long-term outcomes of Graves’ disease in children and adolescents receiving antithyroid drugs vol.26, pp.4, 2009, https://doi.org/10.6065/apem.2040286.143